Bortenat Injection (2mg), which contains the active ingredient Bortezomib, is a potent medication primarily used in the treatment of certain types of blood cancers, including multiple myeloma and some forms of lymphoma. This injectable drug works by inhibiting the proteasome, a cellular complex responsible for degrading unneeded or damaged proteins, thereby disrupting the cancer cell cycle and promoting apoptosis, or programmed cell death. Bortenat Injection is typically administered under the supervision of a healthcare professional, often in a clinical setting, and is formulated to ensure precise dosing and efficacy. The composition of Bortenat includes Bortezomib as the active ingredient, along with various excipients that aid in its stability and delivery. This medication is crucial for patients battling aggressive hematological malignancies, offering hope for improved outcomes and quality of life.